Chengcheng Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chengcheng Gong has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Biyun Wang
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3 shared publications - Xichun Hu
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
3 shared publications - Jian Zhang
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publications Jun Cao
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publicationsLeiping Wang
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publicationsMingchuan Zhao
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 shared publications
Latest Publications
- 4 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26) , 2543-2553
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
PURPOSE: Brain metastases (BMs) of triple-negative breast cancer (TNBC) are lethal, often associated with a limited life span and lack of effective antitumor agents. Here we reported a triple combination therapy consisting of adebrelimab, bevacizumab, and cisplatin/carboplatin in BMs of TNBC. METHODS: This phase II clinical trial involved patients with TNBC with active BMs. Participants were administered with adebrelimab, bevacizumab, and cisplatin/carboplatin until disease progression or unacceptable toxic effects. The primary end point was the objective response rate in CNS (CNS-ORR) according to the Response Assessment in Neuro-Oncology BMs criteria, and the secondary end points included the clinical benefit rate in CNS (CNS-CBR), progression-free survival (PFS), overall survival (OS), the first progression site, and safety. RESULTS: A total of 35 patients were enrolled and treated, and the median lines of previous treatment were 2 (range, 0-4). The confirmed CNS-ORR was 77.1% (27/35, 95% CI, 59.9 to 89.6), and the CNS-CBR was 80.0% (28/35, 95% CI, 63.1 to 91.6). The median overall PFS was 8.3 months (95% CI, 5.8 to 11.5), whereas the median CNS-PFS was 10.3 months (95% CI, 7.4 to 14.3) and the median OS was 21.1 months (95% CI, 13.2 to not reached). Among the 28 patients who progressed, progression was intracranial-only in 32.1% (9/28) patients, extracranial-only in 35.7% (10/28) patients, and both in 32.1% (9/28) patients. The incidence of grade ≥3 treatment-related adverse events was 65.7% (23/35). Treatment-related serious adverse events occurred in five patients (14.3%), and no treatment-related deaths were reported. CONCLUSION: The combination of adebrelimab, bevacizumab, and cisplatin/carboplatin was the first regimen to demonstrate promising intracranial antitumor activity and prolonged PFS and CNS-PFS, along with a manageable safety profile, warranting further investigation.
- 4 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26) , 2543-2553
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
PURPOSE: Brain metastases (BMs) of triple-negative breast cancer (TNBC) are lethal, often associated with a limited life span and lack of effective antitumor agents. Here we reported a triple combination therapy consisting of adebrelimab, bevacizumab, and cisplatin/carboplatin in BMs of TNBC. METHODS: This phase II clinical trial involved patients with TNBC with active BMs. Participants were administered with adebrelimab, bevacizumab, and cisplatin/carboplatin until disease progression or unacceptable toxic effects. The primary end point was the objective response rate in CNS (CNS-ORR) according to the Response Assessment in Neuro-Oncology BMs criteria, and the secondary end points included the clinical benefit rate in CNS (CNS-CBR), progression-free survival (PFS), overall survival (OS), the first progression site, and safety. RESULTS: A total of 35 patients were enrolled and treated, and the median lines of previous treatment were 2 (range, 0-4). The confirmed CNS-ORR was 77.1% (27/35, 95% CI, 59.9 to 89.6), and the CNS-CBR was 80.0% (28/35, 95% CI, 63.1 to 91.6). The median overall PFS was 8.3 months (95% CI, 5.8 to 11.5), whereas the median CNS-PFS was 10.3 months (95% CI, 7.4 to 14.3) and the median OS was 21.1 months (95% CI, 13.2 to not reached). Among the 28 patients who progressed, progression was intracranial-only in 32.1% (9/28) patients, extracranial-only in 35.7% (10/28) patients, and both in 32.1% (9/28) patients. The incidence of grade ≥3 treatment-related adverse events was 65.7% (23/35). Treatment-related serious adverse events occurred in five patients (14.3%), and no treatment-related deaths were reported. CONCLUSION: The combination of adebrelimab, bevacizumab, and cisplatin/carboplatin was the first regimen to demonstrate promising intracranial antitumor activity and prolonged PFS and CNS-PFS, along with a manageable safety profile, warranting further investigation.
- Open Access
- 20 November 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China
Background: Platinum-based chemotherapy has demonstrated superior efficacy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC), at a cost of higher toxicity. Reliable prognostic tools are needed to refine risk stratification and facilitate individualized treatment discussions. Objectives: To develop and validate prognostic nomograms for overall survival (OS) and progression-free survival (PFS) in patients with mTNBC receiving first-line platinum-based chemotherapy. Design: Patient-level pooled analysis of prospective trial data, with internal and external validation. Methods: Individual patient-level data of 777 mTNBC patients from 5 prospective clinical trials were collected. In total, 445 patients who received first-line platinum-based chemotherapy at our center were included as the PFP-TNBC cohort, which was randomly divided (7:3) into training and validation sets. An independent real-world cohort of 216 mTNBC patients was used for external validation. Multivariable Cox regression was used to construct OS and PFS models based on clinical characteristics, laboratory biomarkers, and regimen choice. Model performance was evaluated using concordance index (C-index), time-dependent area under the curve (AUC), calibration, and decision curve analysis. Results: Both nomograms included the number of metastatic sites and the choice of platinum combination agent. The OS model additionally incorporated baseline cancer antigen 125 and lactate dehydrogenase; the PFS model included liver metastasis, baseline pain, and CA153 and carcinoembryonic antigen. For OS, the C-indexes were 0.67, 0.66, and 0.65 in the training, internal validation, and external cohorts, with AUCs of 0.71–0.74, 0.71–0.75, and 0.69–0.71 for 1-, 2-, and 3-year OS. For PFS, the C-indexes were 0.66, 0.62, and 0.61 in the training, internal validation, and external cohorts, with AUCs of 0.69–0.80, 0.66–0.74, and 0.63–0.72 for 6-, 12-, and 24-month PFS, respectively. Both models demonstrated good calibration and risk stratification identified groups with significantly different survival outcomes (log-rank p < 0.001). Conclusion: The PFP-TNBC-OS and PFP-TNBC-PFS nomograms provide practical tools to estimate outcomes in mTNBC patients treated with first-line platinum chemotherapy. While C-index values indicated modest discrimination, time-dependent AUCs showed good accuracy at clinically relevant intervals. These models may aid risk stratification, patient counseling, and shared decision-making in chemotherapy-only settings. Future studies are warranted to evaluate their applicability in the evolving era of chemoimmunotherapy.
- 20 November 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessDevelopment and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China
Background: Platinum-based chemotherapy has demonstrated superior efficacy as a first-line treatment for metastatic triple-negative breast cancer (mTNBC), at a cost of higher toxicity. Reliable prognostic tools are needed to refine risk stratification and facilitate individualized treatment discussions. Objectives: To develop and validate prognostic nomograms for overall survival (OS) and progression-free survival (PFS) in patients with mTNBC receiving first-line platinum-based chemotherapy. Design: Patient-level pooled analysis of prospective trial data, with internal and external validation. Methods: Individual patient-level data of 777 mTNBC patients from 5 prospective clinical trials were collected. In total, 445 patients who received first-line platinum-based chemotherapy at our center were included as the PFP-TNBC cohort, which was randomly divided (7:3) into training and validation sets. An independent real-world cohort of 216 mTNBC patients was used for external validation. Multivariable Cox regression was used to construct OS and PFS models based on clinical characteristics, laboratory biomarkers, and regimen choice. Model performance was evaluated using concordance index (C-index), time-dependent area under the curve (AUC), calibration, and decision curve analysis. Results: Both nomograms included the number of metastatic sites and the choice of platinum combination agent. The OS model additionally incorporated baseline cancer antigen 125 and lactate dehydrogenase; the PFS model included liver metastasis, baseline pain, and CA153 and carcinoembryonic antigen. For OS, the C-indexes were 0.67, 0.66, and 0.65 in the training, internal validation, and external cohorts, with AUCs of 0.71–0.74, 0.71–0.75, and 0.69–0.71 for 1-, 2-, and 3-year OS. For PFS, the C-indexes were 0.66, 0.62, and 0.61 in the training, internal validation, and external cohorts, with AUCs of 0.69–0.80, 0.66–0.74, and 0.63–0.72 for 6-, 12-, and 24-month PFS, respectively. Both models demonstrated good calibration and risk stratification identified groups with significantly different survival outcomes (log-rank p < 0.001). Conclusion: The PFP-TNBC-OS and PFP-TNBC-PFS nomograms provide practical tools to estimate outcomes in mTNBC patients treated with first-line platinum chemotherapy. While C-index values indicated modest discrimination, time-dependent AUCs showed good accuracy at clinically relevant intervals. These models may aid risk stratification, patient counseling, and shared decision-making in chemotherapy-only settings. Future studies are warranted to evaluate their applicability in the evolving era of chemoimmunotherapy.
- Open Access
- 3 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs
Most of current ADCs have the problems of heterogeneity and payload-mediated off-target toxicities due to random conjugation and unstable linker. Herein we apply site-specific ligase-dependent conjugation (LDC) for GQ1001 and GQ1005, where humanized anti-HER2 antibody is linked to DM1 and DXd, respectively, via stable ring-opening linker. GQ1001 exhibits HER2 expression-dependent activity (contrary to T-DM1), indicating decreased off-target toxicity. The biostability of GQ1001 and GQ1005 in plasma is more favorable, and pharmacokinetics and safety profiles are improved in cynomolgus-monkeys with decreased circulating free-toxin levels. GQ1001 and GQ1005 are effective in animal models against pretreated HER2-positive cancers insensitive to HER2-targeting and/or chemotherapeutic drugs. The efficacy of GQ1001 is supra-additively enhanced by tyrosine-kinase inhibitors or chemotherapy, with manageable toxicity. GQ1001 is efficacious in cancers resistant to T-DXd due to high ABCG2 expression. Together, the LDC technology and ring-opening linker improve the stability and safety in GQ1001 and GQ1005 for treating refractory HER2-positive cancers.
- 3 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessSite-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs
Most of current ADCs have the problems of heterogeneity and payload-mediated off-target toxicities due to random conjugation and unstable linker. Herein we apply site-specific ligase-dependent conjugation (LDC) for GQ1001 and GQ1005, where humanized anti-HER2 antibody is linked to DM1 and DXd, respectively, via stable ring-opening linker. GQ1001 exhibits HER2 expression-dependent activity (contrary to T-DM1), indicating decreased off-target toxicity. The biostability of GQ1001 and GQ1005 in plasma is more favorable, and pharmacokinetics and safety profiles are improved in cynomolgus-monkeys with decreased circulating free-toxin levels. GQ1001 and GQ1005 are effective in animal models against pretreated HER2-positive cancers insensitive to HER2-targeting and/or chemotherapeutic drugs. The efficacy of GQ1001 is supra-additively enhanced by tyrosine-kinase inhibitors or chemotherapy, with manageable toxicity. GQ1001 is efficacious in cancers resistant to T-DXd due to high ABCG2 expression. Together, the LDC technology and ring-opening linker improve the stability and safety in GQ1001 and GQ1005 for treating refractory HER2-positive cancers.
- Open Access
- 15 July 2023
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 55 (3) , 1001-1010
Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study
Purpose Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy that occurs primarily in children and adolescents. The clinical and pathological features of IMT in adult patients are not well understood.Materials and Methods We retrospectively searched for records of adult patients with IMT at Fudan University Shanghai Cancer Center from 2006 to 2021. Clinicopathological data, treatments, and outcomes were collected and analyzed.Results Thirty adult patients with IMT, mostly women (60.0%), were included. The median age of the patients was 38 (21-77). The most common primary site was abdominopelvic region (53.3%), followed by lungs (20.0%). Seven patients had an abdominal epithelioid inflammatory myofibroblast sarcoma (EIMS). The positivity rate of anaplastic lymphoma kinase (ALK) was 81.5% (22/27). Sixteen patients with advanced ALK-positive disease received crizotinib, with an objective response rate (ORR) of 81.3% and a disease control rate of 87.5%. The median progression-free survival was 20.8 months. EIMS was associated with more aggressive behavior; however, the prognosis was similar to that of non-EIMS patients after treatment with an ALK inhibitor. At a median follow-up time of 30 months (95% confidence interval [CI], 13.6 to 46.4), the 5-year overall survival was 77% (95% CI, 66 to 88) in all patients.Conclusion Adult IMTs appeared more aggressive, with a higher incidence of recurrence and metastases, and patients with EIMS had more aggressive cases. Treatment with ALK inhibitors resulted in a high ORR and a durable response, which suggested that ALK inhibitors could be used as a first-line treatment option in adult patients with ALK-positive advanced IMT.
- 15 July 2023
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 55 (3) , 1001-1010
Open AccessClinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study
Purpose Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy that occurs primarily in children and adolescents. The clinical and pathological features of IMT in adult patients are not well understood.Materials and Methods We retrospectively searched for records of adult patients with IMT at Fudan University Shanghai Cancer Center from 2006 to 2021. Clinicopathological data, treatments, and outcomes were collected and analyzed.Results Thirty adult patients with IMT, mostly women (60.0%), were included. The median age of the patients was 38 (21-77). The most common primary site was abdominopelvic region (53.3%), followed by lungs (20.0%). Seven patients had an abdominal epithelioid inflammatory myofibroblast sarcoma (EIMS). The positivity rate of anaplastic lymphoma kinase (ALK) was 81.5% (22/27). Sixteen patients with advanced ALK-positive disease received crizotinib, with an objective response rate (ORR) of 81.3% and a disease control rate of 87.5%. The median progression-free survival was 20.8 months. EIMS was associated with more aggressive behavior; however, the prognosis was similar to that of non-EIMS patients after treatment with an ALK inhibitor. At a median follow-up time of 30 months (95% confidence interval [CI], 13.6 to 46.4), the 5-year overall survival was 77% (95% CI, 66 to 88) in all patients.Conclusion Adult IMTs appeared more aggressive, with a higher incidence of recurrence and metastases, and patients with EIMS had more aggressive cases. Treatment with ALK inhibitors resulted in a high ORR and a durable response, which suggested that ALK inhibitors could be used as a first-line treatment option in adult patients with ALK-positive advanced IMT.
- 16 July 2019
- Published by Springer Nature in Hydrogeology Journal
- Vol. 27 (7) , 2707-2718
Assessing bare-soil evaporation from different water-table depths using lysimeters and a numerical model in the Ordos Basin, China
- 16 July 2019
- Published by Springer Nature in Hydrogeology Journal
- Vol. 27 (7) , 2707-2718
Assessing bare-soil evaporation from different water-table depths using lysimeters and a numerical model in the Ordos Basin, China
- Open Access
- 17 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (35) , 59810-59822
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
- 17 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (35) , 59810-59822
Open AccessEfficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study